1. Multitarget Compounds for Bipolar Disorder: From Rational Design to Preliminary Pharmacokinetic Evaluation.
- Author
-
Di Martino RMC, Bottegoni G, Seghetti F, Russo D, Penna I, De Simone A, Ottonello G, Mandrup Bertozzi S, Armirotti A, Bandiera T, Belluti F, and Cavalli A
- Subjects
- Antipsychotic Agents chemical synthesis, Antipsychotic Agents chemistry, Bipolar Disorder metabolism, Dose-Response Relationship, Drug, Glycogen Synthase Kinase 3 beta antagonists & inhibitors, Glycogen Synthase Kinase 3 beta metabolism, Humans, Molecular Structure, Receptors, Dopamine D3 agonists, Receptors, Dopamine D3 metabolism, Structure-Activity Relationship, Antipsychotic Agents pharmacokinetics, Bipolar Disorder drug therapy, Drug Design
- Abstract
Due to the complex and multifactorial nature of bipolar disorder (BD), single-target drugs have traditionally provided limited relief with no disease-modifying effects. In line with the polypharmacology paradigm, we attempted to overcome these limitations by devising two series of multitarget-directed ligands endowed with both a partial agonist profile at dopamine receptor D3 (D3R) and inhibitory activity against glycogen synthase kinase 3 beta (GSK-3β). These are two structurally unrelated targets that play independent, yet connected, roles in cognition and mood regulation. Two compounds (7 and 10) emerged as promising D3R/GSK-3β multitarget-directed ligands with nanomolar activity at D3R and low-micromolar inhibition of GSK-3β, thereby confirming, albeit preliminarily, the feasibility of our strategy. Furthermore, 7 showed promising drug-like properties in stability and pharmacokinetic studies., (© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2020
- Full Text
- View/download PDF